Home › Disorders of Excessive Somnolence
Disorders of Excessive Somnolence clinical trials recruiting in the U.S.
16 studies for Disorders of Excessive Somnolence are recruiting participants at sites across the United States.
Cities with the most studies
- Cincinnati, OH9 studies
- Atlanta, GA9 studies
- San Antonio, TX9 studies
- Miami, FL8 studies
- Charlotte, NC8 studies
- Austin, TX7 studies
- Sugar Land, TX7 studies
- Columbia, SC7 studies
- Orlando, FL7 studies
- Lansing, MI6 studies
- Brandon, FL6 studies
- Staten Island, NY5 studies
- Dallas, TX5 studies
- Los Angeles, CA5 studies
- Reading, PA5 studies
- Macon, GA5 studies
- Houston, TX4 studies
- Baltimore, MD4 studies
- Colorado Springs, CO4 studies
- Farmington Hills, MI4 studies
- Boulder, CO4 studies
- Philadelphia, PA4 studies
- Frisco, TX4 studies
- Chicago, IL3 studies
- Spokane, WA3 studies
- St. Louis, MO3 studies
- Kansas City, KS3 studies
- Phoenix, AZ3 studies
- Madison, WI3 studies
- Sterling Heights, MI3 studies
- Columbus, OH3 studies
By state
- Alabama8 studies
- Arizona6 studies
- California8 studies
- Colorado7 studies
- Florida11 studies
- Georgia10 studies
- Illinois5 studies
- Kansas3 studies
- Maryland4 studies
- Massachusetts5 studies
- Michigan8 studies
- Minnesota3 studies
- Missouri4 studies
- Nevada3 studies
- New Jersey6 studies
- New York4 studies
- North Carolina9 studies
- Ohio10 studies
- Pennsylvania6 studies
- South Carolina9 studies
- Texas11 studies
- Washington3 studies
- Wisconsin4 studies
Recently updated studies
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07500090A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07881757A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
RecruitingPhase 2/3
Ages 18 to 70 · All sexes · Updated Nov 3, 2026 · NCT07598708A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Oct 28, 2026 · NCT07901179Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2026 · NCT01793168Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Oct 13, 2026 · NCT07484217A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
RecruitingPhase 2/3
Ages 18 to 70 · All sexes · Updated Oct 9, 2026 · NCT06767683A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Oct 7, 2026 · NCT07455383A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Oct 7, 2026 · NCT07540897A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Oct 7, 2026 · NCT07502443A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07540364A Study of Pitolisant in Patients With Prader-Willi Syndrome
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Aug 25, 2026 · NCT06366464Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT06568367Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Jun 9, 2026 · NCT06170970A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Apr 16, 2026 · NCT07096674A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 80 · All sexes · Updated Dec 24, 2025 · NCT07082829From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.